Marcel Zwaal
Directeur Général chez Gadeta BV
Provenance du réseau au premier degré de Marcel Zwaal
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Extinct | Pharmaceuticals: Major | 8 | |
Gadeta BV
 Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands.
4
| Subsidiary | Medical Specialties | 4 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Marcel Zwaal via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| ASTRAZENECA PLC | Pharmaceuticals: Major | Public Communications Contact Corporate Officer/Principal | |
Genencor International, Inc.
 Genencor International, Inc. BiotechnologyHealth Technology Genencor International, Inc. develops and manufactures enzyme product solutions for industrial, agricultural and health care markets. It finds genes and alters their proteins for use in cleaning, textile, health care, food and animal feed products using gene discovery, molecular evolution, functional genomics and immunology techniques. The company also develops solutions for the biofuels, biodefense and biosafety industries. Genencor International was founded in 1982 and is located in Rochester, NY. | Biotechnology | Investor Relations Contact | |
| KERYX BIOPHARMACEUTICALS | Pharmaceuticals: Major | Comptroller/Controller/Auditor Public Communications Contact | |
| IDENIX PHARMACEUTICALS INC | Pharmaceuticals: Major | Investor Relations Contact | |
| AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member | |
| MORPHOSYS AG | Biotechnology | Corporate Officer/Principal | |
| Imperial College London | College/University | Undergraduate Degree | |
Index Ventures SA
 Index Ventures SA Investment ManagersFinance Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland. | Investment Managers | Private Equity Analyst | |
| PHARMING GROUP N.V. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| University of Leeds | College/University | Undergraduate Degree | |
Monash University
 Monash University Other Consumer ServicesConsumer Services Monash University operates as a public research university. It specializes in higher education, global engagement, postgraduate courses, undergraduate study, and PhD research. The company was founded on March 1961 and is headquartered in Clayton, Australia. | College/University | Doctorate Degree | |
| Bentley University | College/University | Masters Business Admin | |
| The University of Texas at Austin | College/University | Doctorate Degree | |
| Salem International University | College/University | Undergraduate Degree | |
| ABLYNX | Biotechnology | Chief Tech/Sci/R&D Officer | |
| University of Warwick | College/University | Doctorate Degree | |
| University College London | College/University | Doctorate Degree | |
| University of Leiden | College/University | Corporate Officer/Principal Doctorate Degree | |
| Delft University of Technology | College/University | Graduate Degree | |
| University of Utrecht | College/University | Corporate Officer/Principal Doctorate Degree Graduate Degree | |
| University of Groningen | College/University | Doctorate Degree | |
| AMAG PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Investor Relations Contact | |
| MERUS N.V. | Biotechnology | Chief Operating Officer | |
| Manchester Business School | College/University | Masters Business Admin | |
Crossbeta Biosciences BV
 Crossbeta Biosciences BV BiotechnologyHealth Technology Crossbeta Biosciences BV develops drug discovery programs in the area of misfolded protein diseases. It specializes in alzheimer's disease drug development and drug discovery platform services. The company was founded by Martijn Gebbink and Barend Bouma in 2005 and is headquartered in Utrecht, the Netherlands. | Biotechnology | Director/Board Member | |
| MENDUS AB | Biotechnology | Corporate Officer/Principal | |
Cristal Delivery BV
 Cristal Delivery BV Pharmaceuticals: MajorHealth Technology Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
Janssen Research & Development LLC
 Janssen Research & Development LLC Miscellaneous Commercial ServicesCommercial Services Part of Johnson & Johnson, Janssen Research & Development LLC is a company that provides research and development medicines and solutions to other medical needs. The company is based in Raritan, NJ. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| IDOGEN AB (PUBL) | Biotechnology | Director/Board Member | |
| PROQR THERAPEUTICS N.V. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Impatients NV
 Impatients NV Miscellaneous Commercial ServicesCommercial Services Impatients N.V. operates an online platform for drug innovations. It provides physicians and patients that are excluded from clinical trials access to drugs in development via early access programs. The company was founded by Ronald Brus, SJaak Vink, Govert J. Schouten, Witt Jan, Erdem Yavuz, and René Beukema in 2012 and is headquartered in Amsterdam, the United Kingdom. | Miscellaneous Commercial Services | Founder | |
Medicxi Ventures (Jersey) Ltd.
 Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Investment Managers | Founder | |
Janpix Holdings, Inc.
 Janpix Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Janpix Holdings, Inc. engages in provision of research and experimental development on biotechnology. The company was founded by Patrick T. Gunning and Cortes Pierre and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Director/Board Member | |
Fore Biotherapeutics, Inc.
 Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Director/Board Member | |
Aristi Biotech BV
 Aristi Biotech BV BiotechnologyHealth Technology Aristi Biotech BV is a service company dedicated to the preclinical development of monoclonal antibodies. It offers monoclonal antibody generation, cell line development and immunoassay development services. The company is headquartered in Utrecht, the Netherlands. | Biotechnology | Chief Executive Officer | |
| Janssen Biotherapeutics | Corporate Officer/Principal | ||
Ona Therapeutics SL
 Ona Therapeutics SL Pharmaceuticals: MajorHealth Technology Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member | |
Synox Therapeutics Ltd.
 Synox Therapeutics Ltd. BiotechnologyHealth Technology Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland. | Biotechnology | Chief Executive Officer | |
Vaderis Therapeutics AG
 Vaderis Therapeutics AG BiotechnologyHealth Technology Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd. | Biotechnology | Chairman | |
| ELICERA THERAPEUTICS AB | Biotechnology | Director/Board Member | |
| IO BIOTECH, INC. | Biotechnology | Director of Finance/CFO | |
Alethiomics Ltd.
 Alethiomics Ltd. Miscellaneous Commercial ServicesCommercial Services Alethiomics Ltd. operates as a British biotechnology company. The company is based in Cambridge, UK. The company was founded in 2021 by Adam Joseph Mead, Bethan Psaila. The CEO is Mark Throsby. | Miscellaneous Commercial Services | Chief Executive Officer | |
Janssen Global Services LLC
 Janssen Global Services LLC Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Janssen Global Services LLC develops treatments for patients in therapeutic areas of healthcare. The company is based in Raritan, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal |
Statistiques
Internationale
| Pays-Bas | 17 |
| Etats-Unis | 15 |
| Royaume-Uni | 9 |
| Suède | 4 |
| Suisse | 3 |
Sectorielle
| Health Technology | 28 |
| Consumer Services | 14 |
| Commercial Services | 7 |
| Finance | 3 |
| Health Services | 2 |
Opérationnelle
| Corporate Officer/Principal | 26 |
| Director/Board Member | 17 |
| Chief Executive Officer | 11 |
| Doctorate Degree | 10 |
| Public Communications Contact | 10 |
Relations les plus connectées
| Insiders | |
|---|---|
| Mark de Boer | 19 |
| Raymond Barlow | 13 |
| Scott A. Holmes | 9 |
| Giovanni Mariggi | 9 |
| Robert Friesen | 9 |
| Amy Sullivan | 8 |
| Karl Hård | 7 |
| Mark Throsby | 6 |
| Govert J. Schouten | 6 |
| Sharon Longhurst | 6 |
| Margot Hoppe | 5 |
| Jan Feijen | 5 |
- Bourse
- Insiders
- Marcel Zwaal
- Connexions Sociétés
